Hanmi Pharm Co Ltd Total Assets

Latest as of September 2025: ₩2.04 Trillion KRW ≈ $1.38 Billion USD

Hanmi Pharm Co Ltd total assets. Based on the latest financial reports, Hanmi Pharm Co Ltd (128940) holds total assets worth ₩2.04 Trillion KRW (≈ $1.38 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 128940 company net worth for the company's overall valuation and market capitalisation.

Total Assets of Hanmi Pharm Co Ltd (2010–2024)

Total assets of Hanmi Pharm Co Ltd from 2010 to 2024. This chart illustrates how Hanmi Pharm Co Ltd's total assets have evolved over time, based on quarterly financial data. See 128940 share price today for real-time trading data and today's change.

Hanmi Pharm Co Ltd - Asset Composition Analysis

Hanmi Pharm Co Ltd Total Assets Breakdown (December 2024)

Hanmi Pharm Co Ltd total assets breakdown as of December 2024. Hanmi Pharm Co Ltd's total assets of ₩2.04 Trillion consist of 36.9% current assets and 63.1% non-current assets.

Asset Category Amount (KRW) % of Total Assets
Cash & Equivalents ₩0.00 9.5%
Accounts Receivable ₩238.25 Billion 11.8%
Inventory ₩300.93 Billion 14.9%
Property, Plant & Equipment ₩0.00 0.0%
Intangible Assets ₩94.14 Billion 4.7%
Goodwill ₩0.00 0.0%

Asset Composition Trend (2010–2024)

This chart illustrates how Hanmi Pharm Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Hanmi Pharm Co Ltd to assess how much short-term liquidity the company maintains relative to its equity base.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Hanmi Pharm Co Ltd's current assets represent 36.9% of total assets in 2024, an increase from 0.0% in 2010.
  • Cash Position: Cash and equivalents constituted 9.5% of total assets in 2024, up from 1.6% in 2010.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 1.0% in 2010.
  • Asset Diversification: The largest asset category is inventory at 14.9% of total assets.

Hanmi Pharm Co Ltd Competitors by Total Assets

Key competitors of Hanmi Pharm Co Ltd based on total assets are shown below.

Company Country Total Assets
Takeda Pharmaceutical Company Limited
F:TKDA
Germany €15.41 Trillion
Zhejiang Nhu Co Ltd
SHE:002001
China CN¥47.45 Billion
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Germany €1.60 Trillion
Beijing Tongrentang Co Ltd
SHG:600085
China CN¥29.95 Billion
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
China CN¥13.98 Billion
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329
China CN¥11.59 Billion
Neuland Laboratories Limited
NSE:NEULANDLAB
India Rs29.30 Billion
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
China CN¥7.27 Billion

Hanmi Pharm Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.40 1.16 1.15
Quick Ratio 0.86 0.69 0.57
Cash Ratio 0.00 0.00 0.00
Working Capital ₩234.58 Billion ₩97.99 Billion ₩80.92 Billion

Hanmi Pharm Co Ltd - Advanced Valuation Insights

This section examines the relationship between Hanmi Pharm Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 5.53
Latest Market Cap to Assets Ratio 0.00
Asset Growth Rate (YoY) 6.4%
Total Assets ₩2.02 Trillion
Market Capitalization $4.15 Billion USD

Valuation Analysis

Below Book Valuation: The market values Hanmi Pharm Co Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: Hanmi Pharm Co Ltd's assets grew by 6.4% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Hanmi Pharm Co Ltd (2010–2024)

The table below shows the annual total assets of Hanmi Pharm Co Ltd from 2010 to 2024.

Year Total Assets Change
2024-12-31 ₩2.02 Trillion
≈ $1.37 Billion
+6.43%
2023-12-31 ₩1.90 Trillion
≈ $1.29 Billion
-1.35%
2022-12-31 ₩1.92 Trillion
≈ $1.30 Billion
-0.63%
2021-12-31 ₩1.94 Trillion
≈ $1.31 Billion
+2.91%
2020-12-31 ₩1.88 Trillion
≈ $1.28 Billion
-1.66%
2019-12-31 ₩1.91 Trillion
≈ $1.30 Billion
+13.16%
2018-12-31 ₩1.69 Trillion
≈ $1.15 Billion
+1.82%
2017-12-31 ₩1.66 Trillion
≈ $1.13 Billion
+4.01%
2016-12-31 ₩1.60 Trillion
≈ $1.08 Billion
-7.29%
2015-12-31 ₩1.72 Trillion
≈ $1.17 Billion
+66.70%
2014-12-31 ₩1.03 Trillion
≈ $700.28 Million
+17.31%
2013-12-31 ₩880.87 Billion
≈ $596.95 Million
+5.42%
2012-12-31 ₩835.59 Billion
≈ $566.27 Million
+6.07%
2011-12-31 ₩787.75 Billion
≈ $533.85 Million
+5.35%
2010-12-31 ₩747.72 Billion
≈ $506.72 Million
--

About Hanmi Pharm Co Ltd

KO:128940 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$4.15 Billion
₩6.13 Trillion KRW
Market Cap Rank
#3935 Global
#82 in Korea
Share Price
₩483500.00
Change (1 day)
+1.79%
52-Week Range
₩311500.00 - ₩626000.00
All Time High
₩666173.23
About

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two activ… Read more